Correction: Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: Evaluating the Comparative Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in New-Onset Gastric Cancer and Related Gastric Conditions Among Type 2 Diabetes Patients: A Population-Based Cohort Analysis

  • By

  • Oscar Hou In Chou

  • Vinod Kumar Chauhan

  • Cheuk To Skylar Chung

  • Lei Lu

  • Teddy Tai Loy Lee

  • Zita Man Wai Ng

  • Karin Kai Wing Wang

  • Sharen Lee

  • Haipeng Liu

  • Ronald Ting Kai Pang

  • Apichat Kaewdech

  • Bernard Man Yung Cheung

  • Gary Tse

  • Jiandong Zhou

  • August 31, 2026

Share

Clinical Report: Erratum on SGLT2 Inhibitors in Gastric Cancer Among Diabetes Patients

Overview

This erratum corrects affiliation details in the original article evaluating the efficacy of SGLT2 inhibitors in patients with type 2 diabetes and gastric cancer.

Background

The rising incidence of type 2 diabetes presents a significant clinical challenge, necessitating effective therapeutic strategies. SGLT2 inhibitors are among the commonly prescribed medications for managing diabetes.

Data Highlights

This article is a correction notice and does not contain numerical data or trial results.

Key Findings

  • The original article's affiliation details were found to be inaccurate.
  • SGLT2 inhibitors are frequently prescribed for type 2 diabetes management.
  • Comparative efficacy of SGLT2 inhibitors and DPP-4 inhibitors is a relevant area of research.

Clinical Implications

Accurate reporting of clinical research findings is essential for healthcare professionals to make informed decisions. The correction of affiliation details underscores the importance of maintaining integrity in published research.

Conclusion

This erratum serves as a reminder of the necessity for precision in clinical publications, which is vital for advancing patient care and research integrity.

Related Resources & Content

  1. Gastric Cancer, 2024 -- Erratum: Evaluating the Comparative Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors
  2. Frontiers in Endocrinology — Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study
  3. MDSpire News — SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk
  4. MDSpire News — SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis
  5. Frontiers in Endocrinology — SodiuM glucose cotrANsporter-2 (SGLT-2) inhibitors in the treatment of type II DiAbetes in Tuscany: utiLizatiOn patteRns, and relatEd clinical use evaluation; the MANDALORE study protocol
  6. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline | ASCO Publications
  7. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
  8. Safety evaluation of Sodium-glucose cotransporter 2 inhibitors for cancer risk in specific populations: systematic review and meta-analysis - PMC

Original Source(s)

Correction: Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study

  • by Oscar Hou In Chou, Vinod Kumar Chauhan, Cheuk To Skylar Chung, Lei Lu, Teddy Tai Loy Lee, Zita Man Wai Ng, Karin Kai Wing Wang, Sharen Lee, Haipeng Liu, Ronald Ting Kai Pang, Apichat Kaewdech, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou

  • August 31, 2026

Related Content

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

  • August 31, 2026

  • 5 min
Molecular Diagnostics Go Mobile

A smartphone-linked fluorimeter detects infectious disease and cancer biomarkers in 10-minute assays

  • August 31, 2026

  • 3 min